Followers | 36 |
Posts | 2,689 |
Boards Moderated | 0 |
Alias Born | 06/09/2011 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Here is more for you on your wonderful Knight Capital Group.They laugh at FINRA on a miniscule $105k fine. They just keep doing it over and over.
WHISTLEBLOWER VINDICATED: MASSIVE TRADING FIRM KNIGHT CAPITAL CHARGED WITH ABUSING “NAKED SHORTS”
David Dayen
December 15 2016, 11:53 a.m.
Scotty who was the largest of naked short sellers on MAXD Citadel and Knight. (link below)
ANALYSIS and ACTION
We have analyzed the last year of daily short volume data and correlated it to recent market making activity in MAXD. In 27 of the past 31 trading days, 87% of the time, the combined selling and short selling in MAXD has far exceeded the amount of buying (See NetNet column below). Market makers, by definition, are required to PROVIDE LIQUIDITY not extract or remove liquidity. The math provided below demonstrates that instead of matching orders, market makers, Knight/Virtu, Cantor Fitzgerald, Canaccord Genuity, Citadel, eTrade/G1 are heavily shorting MAXD stock BOTH on the offer and on the bid, which by definition means they have a “speculative short selling strategy” running on MAXD. They are carrying net short positions overnight and continuing to claim the market maker’s exemption, which is in VIOLATION of the Fair Market Making Requirements of Regulation SHO. We are able to mathematically prove this because there is not enough BuyVol (buy volume) to match the amount of selling and short selling. The chart below identifies the top 5 market makers, in MAXD for May 2018 (highlighted below) accounting for 2,257,870,595 shares of trading, or 88.22% of total trading volume in May.
Total Volume Name
(Last Month)
643,662,180 Knight/Virtu,
154,447,100 Cantor Fitzgerald,
203,762,081 Canaccord Genuity,
769,731,954 Citadel,
247,276,817 Trade/G1
Highlighting these Market Makers abusive activities in-concert with each other for just the one month of May, allows regulators, the SEC, FINRA, the U.S. Attorney as well as the media to easily identify the manipulative trading activity and counterfeiting of MAXD shares engaged in by their traders for the past year and well beyond. When overlaid for the entire year (back to June 1, 2017) the math is shocking. 8,117,878,650 total shares have been shorted representing in excess of 40% of MAXD’s total trading volume and it demonstrates that these market makers have knowingly participated in manipulative trading practices and counterfeiting of MAXD shares.
https://globenewswire.com/news-release/2018/06/14/1524626/0/en/Explains-Illegal-Naked-Shorting-Being-Perpetrated-By-Major-Market-Makers-on-MAXD-Shares.html
abeta, great find and post on real Naked Shorting!! Interesting these same MM's we have been seeing daily manipulating trading on NWBO are doing the same thing IMO. I believe in the very near future NWBO management will PR their investigation from Mr. Black, SEC and DOJ and I believe there will be criminal intent involved and will be big news just after NWBO announces their paradigm shifting top line results. This is just my opinion.
Great post iwasadiver! I agree with you on this 100%
Great post survivor1x and agree with all of your very good points on where we are to the finish line. Thanks for sharing.
GLTA patients and caregivers in this trial. God bless them.
mkaiz, did you sell your ILNS for the loss on taxes?
Looks very well like it could be as CLSN has a very good clinical pipeline and Thermadox due in 2019! GLTA!
Great post BSB and nice summary of what I also feel is happening based on recent SEC filings. Patience is a virtue and many of us longs have had patience....we have rounded third base and closing in on a home run IMHO.
Obviously this organization https://professorhealth.org/ felt it was important to reference this to their readership. Why does it matter to you if they decided it was important enough to post it to their web site?
My condolences Gus on the loss of a family member to GBM. I can not even comprehend how tough it must be on families.
I pray DCVax-L is the start of a paradigm shifting change with GBM as well as all operable and inoperable tumors. The most recent presentation on blinded date through November 2018 was very telling the trend is even better than blinded date from 2017 presented earlier this year.
God bless all patients and caregivers for participating in this trial.
Brain cancer vaccine works well in some people
November 23, 2018
https://professorhealth.org/2018/11/brain-cancer-vaccine-works-well-in-some-people/
GGB, 100% dead on with this post. Why are all these posts by Ex, ICLight bashing NWBO and they have no shares at all to keep longs from getting burned. They are here for a reason IMHO to discourage new investors and discourage longs who have been waiting for top line results.
GLTA patients, families and many thank you’d to all participants in this trial!
Well said Mi Dendream agree with you 100% on this post!
Phase III trial of DCVax-L shows continued benefits in brain cancer.- Northwest Biotherapeutics.
Drug news
ADDED
1 day ago on 20 November 2018
Data from Pharmawand - Curated by EPG Health - Date added 20 November 2018
John Trusheim, was the PI for DCvax-L Abbot Northwestern Hospital in Minneapolis. Interesting that this reported post is similar the Kat's Cure tumor completely gone after DCVax-L that DocLogic points out frequently. Another positive patient story showing how effective the vaccine is.
Good luck to all patients, longs and NWBO going into next week!
Sojo....what is next level of resistance you are seeing? The MM's keeping pushing ask down below $.25 all day today. Would like to see some large buy volume move in this afternoon into close.
Thanks for all you do on this board and love your charts and information provided.
Got the same feeling Tilt!!
Nice little bread crumb in the filing!
AMRN Pre-Market: think manipulation going on with 2 shares sold to drop PPS lower.the attack today looks to continue to drive PPS lower IMO
I will look to pickup more shares if goes below $14 today
Pre-Market Time (ET) Pre-Market Price Pre-Market Share Volume
06:34:39 $ 14.73 2
06:13:21 $ 14.99 300
05:58:25 $ 14.90 1,000
05:58:25 $ 14.89 398
H2R agree with you 100% on this post!
Senti great point as many if not all of the Preferred Series A participants I believe were friendly Longs who were in alignment with management.
Great catch Senti as I did not know Dr. Mulholland was one of the 65 physicians of the DCVax-L Journal Paper.
November 26, 2018
Senti, wow that is incredible what transpired with your shares. I have never personally experienced something like this so thank you for sharing.
Yea, no manipulation going on with NWBO shares????
Review Article | OPEN | Published: 05 November 2018
Harnessing the immune system in glioblastoma
Nicholas F. Brown, Thomas J. Carter, Diego Ottaviani & Paul Mulholland
British Journal of Cancer (2018)
https://www.nature.com/articles/s41416-018-0258-8
https://www.nature.com/articles/s41416-018-0258-8/tables/2
These factors may help to explain why these early immunotherapeutic approaches were disappointing,83 and why current focus has moved towards therapies that either prime immune cells to target-specific tumour-associated antigens, or modulate the TME to reverse immune escape (Fig. 2). As yet, only two phase III trials have completed: the EGFRvIII-targeted vaccine rindopepimut in newly diagnosed glioblastoma; and the checkpoint inhibitor nivolumab in relapsed glioblastoma; with neither demonstrating survival advantage.84,85 Phase III trials of checkpoint inhibitors and dendritic cell vaccines are ongoing, with a large number of agents in earlier stages of clinical development including peptide vaccines, adoptive T-cell therapies, oncolytic viruses (OV) and combination therapies (Table 2).
Great post Lykiri, connecting the dots on relationship between all of these companies. Pretty interesting to me...on to something big here IMHO....thanks for sharing!
Halted at 9:26am EST this morning. Expect good news IMO
Celsion Co. (NASDAQ:CLSN) CEO Michael H. Tardugno bought 7,500 shares of the business’s stock in a transaction on Monday, October 29th. The stock was bought at an average price of $2.06 per share, for a total transaction of $15,450.00. Following the purchase, the chief executive officer now directly owns 27,700 shares of the company’s stock, valued at $57,062. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
A hedge fund recently raised its stake in Celsion stock. BlackRock Inc. lifted its holdings in shares of Celsion Co. (NASDAQ:CLSN) by 72.3% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 114,844 shares of the biotechnology company’s stock after acquiring an additional 48,194 shares during the period. BlackRock Inc. owned approximately 0.65% of Celsion worth $339,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 4.76% of the company’s stock.
https://www.fairfieldcurrent.com/2018/11/02/celsion-co-clsn-ceo-acquires-15450-00-in-stock.html
Totally agree with you!
Yes and their PPS is down over 15% today must have been a good one!
Great find and amazed at the following two paragraphs in this document and people think this is not going on in the market.
Is this some type of signal(1 share trades) for today's opening from Nasdaq pre-market volume this morning?
https://www.nasdaq.com/symbol/amrn/premarket
Predicting constitutes acceptance of PredictWallStreet's terms of use.
Trade Detail
Most Active in the Pre-Market
Pre-Market Time (ET) Pre-Market Price Pre-Market Share Volume
04:36:32 $ 20.30 High 1
04:29:05 $ 20.30 1
Hi Dan, when you get an opportunity can you email me your options spreadsheeet at john1045@comcast.net. Many thanks and much appreciated!
Understand Flip as well as other people (Bosch, Boynton and others) having contributed to DCVax platform but for Dr. Liau to receive two prestigious awards in a very short period of time and DCVax-L trial getting to top line results in near future is telling IMO only.
Great point Marzan, excactly what I was thinking after she has received (2) prestigious awards recently the most recent one yesterday.
Robert Hooper, Director at Celsion purchased in open market 10k shares at $2.70. The Directors continue to do this is a good sign IMO. GLTA!
Well said Flip and totally agree with you on this post!
Great find Evaluate! I like this section in the abstract.
This is very encouraging to see this response from their consultation.